4.0 Article

Beliefs about management of irritable bowel syndrome in primary care: cross-sectional survey in one locality

期刊

出版社

CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1463423614000383

关键词

antidepressants; antispasmodics; coeliac disease; fibre; irritable bowel syndrome; probiotics

向作者/读者索取更多资源

Aim: To examine beliefs about irritable bowel syndrome (IBS) management among primary care physicians. Background: There have been considerable advances in evidence synthesis concerning management of IBS in the last five years, with guidelines for its management in primary care published by the National Institute for Health and Care Excellence (NICE). Methods: This was a cross-sectional web-based questionnaire survey of 275 primary care physicians. We emailed a link to a Survey Monkey questionnaire, containing 18 items, to all eligible primary care physicians registered with three clinical commissioning groups in Leeds, UK. Participants were given one month to respond, with a reminder sent out after two weeks. Findings: One-hundred and two (37.1%) primary care physicians responded. Among responders, 70% believed IBS was a diagnosis of exclusion, and > 80% checked coeliac serology often or always in suspected IBS. Between > 50% and > 70% believed soluble fibre, antispasmodics, peppermint oil, and psychological therapies were potentially efficacious therapies. The respondents were less convinced that antidepressants or probiotics were effective. Despite perceived efficacy of psychological therapies, 80% stated these were not easily available. Levels of use of soluble fibre, antispasmodics, and peppermint oil were in the range of 40% to > 50%. Most primary care physicians obtained up-to-date evidence about IBS management from NICE guidelines. Most primary care physicians still believe IBS is a diagnosis of exclusion, and many are reluctant to use antidepressants or probiotics to treat IBS. More research studies addressing diagnosis and treatment of IBS based in primary are required.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Gastroenterology & Hepatology

Immortal time bias in a retrospective study examining colorectal cancer mortality according to adherence to colonoscopy

Conchubhair Winters, Alexander Charles Ford

Review Gastroenterology & Hepatology

Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis

Brigida Barberio, Pierfrancesco Visaggi, Edoardo Savarino, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford

Summary: This study conducted a network meta-analysis to evaluate the efficacy and safety of different medical therapies for endoscopy-negative reflux disease. The results showed that proton pump inhibitors (PPIs) are superior to other drugs in treating this condition. Future research should focus on better patient classification and investigating the efficacy of other drugs.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Article Gastroenterology & Hepatology

Willingness to pay for medications among patients with Rome IV irritable Bowel syndrome

Vivek C. Goodoory, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

Summary: This study examined willingness to pay for medications among individuals with irritable bowel syndrome (IBS). The results showed that women and individuals with an annual income of 30,000 pounds or more were more likely to be willing to pay for medication. In addition, individuals with lower IBS-related quality of life were more willing to pay for a medication that could improve their symptoms.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Review Gastroenterology & Hepatology

Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease

Shahida Din, Christian P. Selinger, Christopher J. Black, Alexander C. Ford

Summary: A network meta-analysis was conducted to examine the risk of Herpes zoster infection associated with biologics and small molecules used to treat inflammatory bowel disease (IBD). The results showed that Janus kinase inhibitors, particularly tofacitinib, were most likely to increase the risk of Herpes zoster infection, and the risk increased with higher doses.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome

Vivek C. C. Goodoory, Elspeth A. A. Guthrie, Cho E. E. Ng, Christopher J. J. Black, Alexander C. C. Ford

Summary: Irritable bowel syndrome (IBS) has a substantial impact on the quality of life of affected individuals, and the negative impact is worse than observed in some severe chronic organic conditions.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Review Gastroenterology & Hepatology

Efficacy and Safety of Drugs for Gastroparesis: Systematic Review and Network Meta-analysis

Maria Rosa Ingrosso, Michael Camilleri, Jan Tack, Gianluca Ianiro, Christopher J. Black, Alexander C. Ford

Summary: This study evaluated the efficacy and safety of drugs for gastroparesis through a network meta-analysis. The results showed that oral dopamine antagonists and tachykinin-1 antagonists were more effective than placebo. For individual symptoms, oral metoclopramide showed good efficacy for nausea, fullness, and bloating. However, the confidence in the evidence for most comparisons was low to moderate, indicating a need for more effective therapies for gastroparesis.

GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Impact of Baseline Disease Activity and Trial Duration on Efficacy of Biologics in Active Crohn's Disease: Meta-analysis

Brigida Barberio, David J. Gracie, Christopher J. Black, Alexander C. Ford

Summary: In this study, the authors conducted a systematic review and meta-analysis to evaluate the impact of criteria used to define CD activity at study entry and the time point used to confirm efficacy on the therapeutic gain of active drug over placebo. The results showed that both factors appeared to be important in maximizing the treatment effect of active drug compared to placebo.

INFLAMMATORY BOWEL DISEASES (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here? Authors' reply

Vivek C. Goodoory, Elspeth A. Guthrie, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome

Vivek C. Goodoory, Cho E. Ng, Christopher J. Black, Alexander C. Ford

Summary: This study compared the characteristics of individuals with irritable bowel syndrome (IBS) reporting faecal incontinence (FI) with those who do not report FI. The results showed that individuals with FI were older, more likely to have IBS-D, had lower education levels and incomes, reported more urgency and more severe IBS and psychological symptoms, had lower quality of life scores, and higher healthcare costs.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

A prospective comparison of UK and Malaysian patients with irritable bowel syndrome in secondary care

Kee-Huat Chuah, Christopher J. Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong-Yeh Lee, Sanjiv Mahadeva, Alexander C. Ford

Summary: By comparing IBS patients from the UK and Malaysia, it was found that UK patients were more likely to consume alcohol, had more frequent symptoms such as pain, bloating, and meal-related issues, higher symptom scores, greater limitation of activities, and a higher likelihood of reporting abnormal anxiety. UK patients also had higher levels of perceived stress, gastrointestinal symptom-specific anxiety, and somatoform symptom-reporting.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply

Vivek C. Goodoory, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: ondansetron for patients with IBS-D and bowel-predominant symptoms-authors' reply

David Gunn, Alexander Ford, Amanda Farrin, Robin Spiller

Summary: This article is related to the papers by Gunn et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Gastroenterology & Hepatology

Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply

Vivek C. Goodoory, Elspeth A. Guthrie, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Gastroenterology & Hepatology

Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome--authors' reply

Vivek C. Goodoory, Cho E. Ng, Christopher J. Black, Alexander C. Ford

Summary: This article is associated with Goodoory et al papers. Click the link to access these articles.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Gastroenterology & Hepatology

Relative Cost-effectiveness of Management Strategies for Uninvestigated Dyspepsia

Alexander C. Ford, Colin W. Howden

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

暂无数据